Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Hemophilia B, or factor IX deficiency, is an X-linked recessive disorder occurring in about 1 in 25,000 males. Affected individuals are at risk for spontaneous bleeding into many organs; treatment mainly consists of the transfusion of clotting factor concentrates prepared from human blood or recombinant sources after bleeding has started. Small- and large-animal models have been developed and/or characterized that closely mimic the human disease state. As a preclinical model for gene therapy, recombinant adeno-associated viral vectors containing the human or canine factor IX cDNAs were infused into the livers of murine and canine models of hemophilia B, respectively. There was no associated toxicity with infusion in either animal model. Constitutive expression of factor IX was observed, which resulted in the correction of the bleeding disorder over a period of over 17 months in mice. Mice with a steady-state concentration of 25% of the normal human level of factor IX had normal coagulation. In hemophilic dogs, a dose of rAAV that was approximately 1/10 per body weight that given to mice resulted in 1% of normal canine factor IX levels, the absence of inhibitors, and a sustained partial correction of the coagulation defect for at least 8 months.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An early clinical trial for the treatment of hemophilia, via i.v. delivery of recombinant AAV (rAAV), resulted in robust CD8 T cell responses and the loss of transgene expression, which was later shown to be mediated by capsid-specific T cell responses.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
In the citing paper
“Capsid-specific T cell responses to AAV-based therapies were not predicted from proof-of-concept studies in animal models but were identified in human studies.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [2]
Citations
Cites
Dranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Samulski, R. J., Chang, L. S., & Shenk, T. (1989) · Journal of Virology · doi:10.1128/jvi.63.9.3822-3828.1989 · Cited by 743
A "humanized" green fluorescent protein cDNA adapted for high-level expression in mammalian cells
Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J., & Muzyczka, N. (1996) · Journal of Virology · doi:10.1128/jvi.70.7.4646-4654.1996 · Cited by 609
Targeted disruption of the mouse factor VIII gene produces a model of haemophilia A
Bi, L., Lawler, A. M., Antonarakis, S. E., High, K. A., Gearhart, J. D., & Kazazian, H. H. (1995) · Nature Genetics · doi:10.1038/ng0595-119 · Cited by 593
Dai, Y., Schwarz, E. M., Gu, D., Zhang, W. W., Sarvetnick, N., & Verma, I. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.5.1401 · Cited by 591
Snyder, R. O., Miao, C. H., Patijn, G. A., Spratt, S. K., Danos, O., Nagy, D., Gown, A. M., Winther, B., Meuse, L., Cohen, L. K., et al. (1997) · Nature Genetics · doi:10.1038/ng0797-270 · Cited by 579
Self-citationHerzog, R. W., Hagstrom, J. N., Kung, S.-H., Tai, S. J., Wilson, J. M., Fisher, K. J., & High, K. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.11.5804 · Cited by 474
Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice
Smith, T. A. G., Mehaffey, M. G., Kayda, D. B., Saunders, J. M., Yei, S., Trapnell, B. C., McClelland, A., & Kaleko, M. (1993) · Nature Genetics · doi:10.1038/ng1293-397 · Cited by 335
Hellström-Lindberg, E., Ahlgren, T., Beguin, Y., Carlsson, M., Carneskog, J., Dahl, I. M., Dybedal, I., Grimfors, G., Kanter-Lewensohn, L., Linder, O., et al. (1998) · Blood · doi:10.1182/blood.v92.1.68.413k23_68_75 · Cited by 304
In Vivo Gene Therapy of Hemophilia B: Sustained Partial Correction in Factor IX-Deficient Dogs
Kay, M. A., Rothenberg, S., Landen, C. N., Bellinger, D. A., Leland, F., Toman, C., Finegold, M., Thompson, A. R., Read, M. S., Brinkhous, K. M., et al. (1993) · Science · doi:10.1126/science.8211118 · Cited by 304
Self-citationA Coagulation Factor IX-Deficient Mouse Model for Human Hemophilia B
Lin, H.-F., Maeda, N., Smithies, O., Straight, D. L., & Stafford, D. W. (1997) · Blood · doi:10.1182/blood.v90.10.3962 · Cited by 290
Self-citationKay, M. A., Landen, C. N., Rothenberg, S. R., Taylor, L. A., Leland, F., Wiehle, S., Fang, B., Bellinger, D., Finegold, M., & Thompson, A. R. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.6.2353 · Cited by 251
Self-citationRole for highly regulated rep gene expression in adeno-associated virus vector production
Li, J., Samulski, R. J., & Xiao, X. (1997) · Journal of Virology · doi:10.1128/jvi.71.7.5236-5243.1997 · Cited by 227
Nakai, H., Herzog, R. W., Hagstrom, J. N., Walter, J., Kung, S.-H., Yang, E. Y., Tai, S. J., Iwaki, Y., Kurtzman, G. J., Fisher, K. J., et al. (1998) · Blood · doi:10.1182/blood.v91.12.4600 · Cited by 188
The kinetics of rAAV integration in the liver
Miao, C. H., Snyder, R. O., Schowalter, D. B., Patijn, G. A., Donahue, B., Winther, B., & Kay, M. A. (1998) · Nature Genetics · doi:10.1038/ng0598-13 · Cited by 186
Self-citationFactor IX Inhibitors and Anaphylaxis in Hemophilia B
Warrier, I., Ewenstein, B. M., Koerper, M. A., Shapiro, A., Key, N., DiMichele, D., Miller, R. T., Pasi, J., Rivard, G. E., Sommer, S. S., et al. (1997) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-199701000-00003 · Cited by 183
A factor IX-deficient mouse model for hemophilia B gene therapy
Wang, L., Zoppè, M., Hackeng, T. M., Griffin, J. H., Lee, K.-F., & Verma, I. M. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.21.11563 · Cited by 164
Expression of human factor IX in mice after injection of genetically modified myoblasts.
Yao, S.-N., & Kurachi, K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.8.3357 · Cited by 139
Nephrotic Syndrome as a Complication of Immune Tolerance in Hemophilia B
Ewenstein, B. M., Takemoto, C., Warrier, I. A., Lusher, J. M., Saidi, P., Eisele, J., Ettinger, L. J., & DiMichele, D. (1997) · Blood · doi:10.1182/blood.v89.3.1115 · Cited by 130
Human Factor IX Corrects the Bleeding Diathesis of Mice With Hemophilia B
Kung, S., Hagstrom, J. N., Cass, D. L., Tai, S. J., Lin, H.-F., Stafford, D. W., & High, K. A. (1998) · Blood · doi:10.1182/blood.v91.3.784 · Cited by 129
Self-citationA canine model of hemophilic (factor VIII:C deficiency) bleeding
Giles, A. R., Tinlin, S., & Greenwood, R. (1982) · Blood · doi:10.1182/blood.v60.3.727.727 · Cited by 126
Intracellular trafficking of factor VIII to von Willebrand factor storage granules.
Rosenberg, J. B., Foster, P., Kaufman, R. J., Vokac, E., Moussalli, M. J., Kroner, P. A., & Montgomery, R. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1250 · Cited by 117
A deletion mutation causes hemophilia B in Lhasa Apso dogs
Mauser, A., Whitlark, J., Km, W., & Lothrop, C. D. (1996) · Blood · doi:10.1182/blood.v88.9.3451.bloodjournal8893451 · Cited by 82
Primary myoblast-mediated gene transfer: persistent expression of human factor IX in mice.
Sn, Y., Kj, S., & Kurachi, K. (1994) · PubMed · Cited by 82
Targeted Inactivation of the Coagulation Factor IX Gene Causes Hemophilia B in Mice
Kundu, R. K., Sangiorgi, F. O., Wu, L.-Y., Kurachi, K., Anderson, W. F., Maxson, R. E., & Gordon, E. M. (1998) · Blood · doi:10.1182/blood.v92.1.168.413k06_168_174 · Cited by 81
Measurement of Mild Factor VIII Inhibitors in Bethesda Units
Kasper, C. K., & Pool, J. G. (1975) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651380 · Cited by 80
Nichols, T. C., Bellinger, D., Rl, R., Smith, S., Koch, G. G., Davis, K., Sigman, J., Brinkhous, K., Griggs, T. R., & Read, M. (1993) · Blood · doi:10.1182/blood.v81.10.2644.2644 · Cited by 64
Self-citationGriggs, T. R., Webster, W. P., Cooper, H., Wagner, R. H., & Brinkhous, K. M. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.5.2087 · Cited by 58
Self-citationLetter: Measurement of mild factor VIII inhibitors in Bethesda units.
Ck, K., & Jg, P. (1975) · PubMed · Cited by 34
Hemophilic dog model for evaluating therapeutic effectiveness of plasma protein fractions
Kingdon, H. S., & Hassell, T. (1981) · Blood · doi:10.1182/blood.v58.5.868.868 · Cited by 28
Factor VIII in Blood Plasma of Haemophilic Sheep: Analysis of Clotting Time-Plasma Dilution Curves
Neuenschwander, S., & Pliška, V. (2009) · Haemostasis · doi:10.1159/000217077 · Cited by 19
Human Factor IX Corrects the Bleeding Diathesis of Mice With Hemophilia B
Kung, S., Hagstrom, J. N., Cass, D. L., et al. (1998) · Blood · doi:10.1182/blood.v91.3.784.784_784_790 · Cited by 8
Research works printed but not linked: 2
- Brinkhous, K.M. et al. Pharmacokinetics and pharmacodynamics of a B-domain deleted recombinant factor VIII derivative, r-VIII SQ, in canine hemophilia. Thromb. Haemost. 69, 852 (1993 ).
- Brinkhous, K.M., Landen, C.N. & Read, M.S. Evaluation of sensitivity of whole blood clotting time (WBCT), partial thromboplastin time (PTT), and F.IX one-stage bioassay tests with low plasma F.IX levels observed with transfusion or gene therapy in canine hemophilia B. Blood 82, suppl 1 :592a (1993).
Cited by
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Self-citationAdenovirus-Associated Virus Vector–Mediated Gene Transfer in Hemophilia B
Nathwani, A. C., Tuddenham, E. G. D., Rangarajan, S., Rosales, C., McIntosh, J., Linch, D. C., Chowdary, P., Riddell, A., Pie, A. J., Harrington, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1108046 · Cited by 1,864
Self-citationAdeno-associated virus as a delivery vector for gene therapy of human diseases
Wang, J.-H., Gessler, D. J., Zhan, W., Gallagher, T. L., & Gao, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01780-w · Cited by 904
AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B
Manno, C. S., Chew, A. J., Hutchison, S., Larson, P. J., Herzog, R. W., Arruda, V. R., Tai, S. J., Ragni, M. V., Thompson, A., Ozelo, M., et al. (2003) · Blood · doi:10.1182/blood-2002-10-3296 · Cited by 749
Self-citationCd8(+) T-Cell Responses to Adeno-Associated Virus Capsid in Humans
Mingozzi, F., Maus, M. V., Hui, D. J., Sabatino, D. E., Murphy, S. L., Rasko, J. E. J., Ragni, M. V., Manno, C. S., Sommer, J., Jiang, H., et al. (2007) · Nature Medicine · doi:10.1038/nm1549 · Cited by 748
Metadata
- Authors
- Snyder, R. O., Miao, C., Meuse, L., Tubb, J., Donahue, B. A., Lin, H.-F., Stafford, D. W., Patel, S., Thompson, A. R., Nichols, T., Read, M. S., Bellinger, D. A., Brinkhous, K. M., & Kay, M. A.
- Affiliations
- University of Washington (US)
- Stanford Medicine (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Kay, Mark A.
- Venue
- Nature Medicine
- Published
- 1999-01
- Volume
- 5
- Issue
- 1
- Pages
- 64-70
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- DOI
- 10.1038/4751
- OpenAlex
- W1588659566
- Cited by
- 409
- References
- 30
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 3 · 2022: 4 · 2021: 1 · 2020: 5 · 2019: 5 · 2018: 6 · 2017: 3 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 8 · 2012: 12
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01hl001648-50)
- National Heart, Lung, and Blood Institute (HL 53682, R01HL053682, HL-01648)
- Topics
- Health Sciences › Medicine › Hematology › Hemophilia Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- hemophilia B, adeno-associated virus vectors, gene therapy, canine model, mouse model, liver gene transfer, coagulation correction, X-linked bleeding disorder, vector toxicity
- MeSH terms
- Dependovirus, Animals, Antibodies, Bleeding Time, Cell Transformation, Viral, Hemophilia B, Disease Models, Animal, Dogs, Factor IX, Genetic Vectors, Humans, Liver, Mice, Inbred C57BL, Recombination, Genetic, Genetic Therapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.